What is the catalog number for Bevirimat?

The catalog number for Bevirimat is HY-N0842.

What sizes are available for Bevirimat?

Bevirimat is available in the following size(s): 1 mg, 5 mg, 10 mM - 1 mL, 10 mg, 25 mg.

How many pack sizes does Bevirimat come in?

Bevirimat is available in 5 different pack sizes.

Is Bevirimat in stock?

Bevirimat is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Bevirimat?

Bevirimat is manufactured by QuantiMol.

What is the estimated delivery time for Bevirimat?

Estimated delivery time for Bevirimat is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Bevirimat?

The safety data sheet for Bevirimat is available here: http://file.medchemexpress.com/batch_PDF/HY-N0842/Bevirimat-SDS-MedChemExpress.pdf.

Bevirimat

Bevirimat (PA-457, MPC-4326, YK FH312) is an inhibitor of HIV-1 viral particle maturation.Bevirimat specifically inhibits the final rate-limiting step in Gag processing, preventing the release of the mature capsid protein (CA) from its precursor (CA-SP1), resulting in the production of immature non-infectious viral particles. Bevirimat can be used in HIV-1 infection studies[1][2][3][4].

Product Specifications

CAS Number

174022-42-5

Product Name Alternative

PA-457; MPC-4326; YK FH312

UNSPSC

12352211

Target

Virus Protease

Type

Natural Products

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Bevirimat.html

Purity

99.82

Solubility

DMSO : ≥ 50 mg/mL

Smiles

OC([C@]1(CC[C@H]2C(C)=C)[C@@]2([H])[C@](CC[C@@]3([H])[C@]4(CC[C@]5([H])[C@@]3(CC[C@H](OC(CC(C)(C)C(O)=O)=O)C5(C)C)C)C)([H])[C@@]4(C)CC1)=O

Molecular Formula

C36H56O6

Molecular Weight

584.83

References & Citations

[1]Martin DE, et al. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19 (3) :107-13. |[2]Li F, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A. 2003 Nov 11;100 (23) :13555-60. |[3]Blair WS, et al. New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrob Agents Chemother. 2009 Dec;53 (12) :5080-7.|[4]Callies O, et al. Isolation, Structural Modification, and HIV Inhibition of Pentacyclic Lupane-Type Triterpenoids from Cassine xylocarpa and Maytenus cuzcoina. J Nat Prod. 2015 May 22;78 (5) :1045-55. |[5]Qian K, et al. Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors. J Med Chem. 2010 Apr 22;53 (8) :3133-41. |[6]Zhao Y, et al. Design, synthesis, and structure activity relationship analysis of new betulinic acid derivatives as potent HIV inhibitors. Eur J Med Chem. 2021 Apr 5;215:113287.|[7]Qian K, et al. Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors. J Med Chem. 2012 Sep 27;55 (18) :8128-36.|[8]Stoddart CA, et al. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS One. 2007 Nov 28;2 (11) :e1251.|[9]Zhao L, et al. Pre-clinical pharmacological profile of QF-036, a potent HIV-1 maturation inhibitor. Basic Clin Pharmacol Toxicol. 2021 Feb;128 (2) :275-285.